Osteonecrosis of the jaws by intravenous bisphosphonates and osteoradionecrosis: A comparative study

Medicina Oral, Patologia Oral y Cirugia Bucal

Volumn 14, Issue 12, 2009, Pages

  Bagan, Jose V ^a   Jiménez, Yolanda ^a   Hernández, Sergio ^a   Murillo, Judith ^a   Díaz, Jose M ^a   Poveda, Rafael ^a   Carbonell, Enrique ^a   Sanchis, Jose M ^a   Gavaldá, Carmen ^a   Scully, Crispian ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Bisphosphonates; Jaws; Osteonecrosis; Osteoradionecrosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; INTERFERON; PAMIDRONIC ACID; THALIDOMIDE; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE NECROSIS; CONTROLLED STUDY; FEMALE; HUMAN; JAW; JAW FRACTURE; MAJOR CLINICAL STUDY; MALE; RADIATION NECROSIS; SKIN FISTULA; TOOTH EXTRACTION;

DIPHOSPHONATES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; JAW DISEASES; MALE; OSTEONECROSIS; OSTEORADIONECROSIS;

EID: 71949129758     PISSN: 16984447     EISSN: 16986946     Source Type: Journal    
DOI: 10.4317/medoral.14.e616     Document Type: Article

References (21)

1. Aapro MS. Management of bisphosphonate treatment in clinical practice. Semin Oncol. 2007;34:S28-32.
2. Saad F, Lipton A. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol. 2007;34:S17-23. (Pubitemid 350192630)
3. Jeffcoat M, Watts NB. Osteonecrosis of the jaw: balancing the benefits and risks of oral bisphosphonate treatment for osteoporosis. Gen Dent. 2008;56:96-102
4. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479-1491 (Pubitemid 351229318)
5. Marx RE.Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-1117
6. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397-2410
7. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007;29:1548-1558 (Pubitemid 47500128)
8. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, Silvestre FJ, Scully C. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 2005;34:120-123
9. Bagan JV, Jimenez Y, Murillo J, Hernandez S, Poveda R, Sanchis JM, Diaz JM, Scully C. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol. 2006;42:327-329
10. Sanna G, Preda L, Bruschini R, Cossu Rocca M, Ferretti S, Adamoli L, Verri E, Franceschelli L, Goldhirsch A, Nolè F. Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol. 2006;17:1512-1516 (Pubitemid 44542036)
11. Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med. 2006;35:155-160
12. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567-1575 (Pubitemid 41525412)
13. Diel IJ, Fogelman I, Al-Nawas B, Hoffmeister B, Migliorati C, Gligorov J, Väänänen K, Pylkkänen L, Pecherstorfer M, Aapro MS. Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates? Crit Rev Oncol Hematol. 2007;64:198-207.
14. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:433-441 (Pubitemid 44403162)
15. Thorn JJ, Hansen HS, Specht L, Bastholt L. Osteoradionecrosis of the jaws: clinical characteristics and relation to the field of irradiation. J Oral Maxillofac Surg. 2000;58:1088-93; discussion 1093-1095 (Pubitemid 30750198)
16. Kluth EV, Jain PR, Stuchell RN, Frich JC Jr.A study of factors contributing to the development of osteoradionecrosis of the jaws.J Prosthet Dent. 1988;59:194-201.
17. Mounsey RA, Brown DH, O'Dwyer TP, Gullane PJ, Koch GH. Role of hyperbaric oxygen therapy in the management of mandibular osteoradionecrosis. Laryngoscope. 1993;103:605-608 (Pubitemid 23168207)
18. Støre G, Boysen M. Mandibular osteoradionecrosis: clinical behaviour and diagnostic aspects. Clin Otolaryngol Allied Sci. 2000;25:378-384 (Pubitemid 30786144)
19. Koga DH, Salvajoli JV, Alves FA. Dental extractions and radiotherapy in head and neck oncology: review of the literature. Oral Dis. 2008;14:40-44 (Pubitemid 350293990)
20. Bagán J, Blade J, Cozar JM, Constela M, García Sanz R, Gómez Veiga F. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal. 2007;12:E336-40.
21. Walter C, Grötz KA, Kunkel M, Al-Nawas B. Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer. 2007;15:197-202. (Pubitemid 46332925)